Parkinson's Disease - A Comprehensive Overview

Fig. 21.27 - Parkinson Disease: (A) Healthy pigmented substantia nigra, (B) Pallor/depigmentation in PD, (C) Lewy body inclusion in a neuron. - Robbins & Kumar Basic Pathology

1. Definition and Epidemiology

2. Pathophysiology and Neurochemistry

The Dopaminergic System

• The caudate nucleus and putamen become overactive
• Continuous excitatory signals are sent to the corticospinal motor control system
• This excessive excitation leads to rigidity and other motor symptoms
• Feedback circuits begin to oscillate due to loss of inhibitory control, causing the characteristic tremor

Basal Ganglia Circuit Disruption

• Direct pathway (facilitatory to movement): dopamine acts on D1 receptors, normally promoting movement
• Indirect pathway (inhibitory to movement): dopamine acts on D2 receptors, normally suppressing unwanted movements
• Loss of dopamine causes the subthalamic nucleus (STN) to become hyperactive because of reduction of GABA influence - Adams & Victor's Principles of Neurology
• This subthalamic overactivity drives excessive inhibitory output from the globus pallidus internus (GPi) to the thalamus, suppressing motor cortex activity

3. Pathology

Gross Pathology

• Pallor of the substantia nigra and locus coeruleus (visible to the naked eye due to loss of melanin-containing neurons)
• Normal substantia nigra appears dark/black; in PD it appears pale or grey

Microscopic Pathology

• Fine filaments of alpha-synuclein (α-synuclein)
• Neurofilaments
• Ubiquitin
• Associated with Lewy neurites - dystrophic neuritic processes also containing aggregated α-synuclein - Robbins & Kumar Basic Pathology

Alpha-Synuclein: The Core Protein

• Gene mutations (A53T, A30P) that promote oligomerization
• Gene duplication/triplication increasing protein levels
• Defects in autophagy, lysosomal degradation, and the ubiquitin-proteasome system (parkin mutations)
• The protofibrillary form of α-synuclein is directly toxic to dopaminergic neurons
• Dopamine itself can bind to synuclein, enhancing protofibril formation - Adams & Victor's Principles of Neurology

4. Genetics

• Adams & Victor's Principles of Neurology

5. Etiology and Risk Factors

• Genetic factors (as above)
• Environmental toxins: pesticides (organophosphates), industrial chemicals; agrarian/industrialized exposure is slightly more frequent in some studies
• MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine): a synthetic heroin contaminant that selectively destroys the substantia nigra, serving as a neurotoxin model
• Mitochondrial dysfunction: implicated via PINK1 mutations and iron deposition in substantia nigra
• Oxidative stress: dopaminergic neurons are especially vulnerable
• Age is the strongest risk factor; male sex also increases risk

6. Clinical Features

Motor Symptoms (The Classic Tetrad)

1. Tremor - "pill-rolling" resting tremor, 3-6 cycles/sec, present at rest, diminishes with intentional movement (unlike cerebellar tremor). It is involuntary throughout waking hours.
2. Bradykinesia/Akinesia - slowness and difficulty initiating movement. Often the most disabling symptom; patients must exert extreme mental effort for even simple movements, which then occur in a stiff, staccato manner.
3. Rigidity - "cogwheel" or "lead-pipe" rigidity of muscles throughout the body. Due to excessive excitatory output to the motor system.
4. Postural instability - impaired postural reflexes leading to poor balance and falls. Appears later in the disease. - Guyton & Hall; Robbins

• Shuffling gait with reduced arm swing; festination (progressive acceleration of steps)
• Hypomimia (masked face)
• Micrographia (small handwriting)
• Hypophonia (soft speech)
• Dysphagia (swallowing difficulty) - present in up to 82% by objective measures
• Postural changes (stooped posture)

Non-Motor Symptoms

• Sleep disturbances - REM sleep behavior disorder (RBD) can precede motor symptoms by years
• Depression and anxiety - very common; anxiety affects quality of life significantly
• Autonomic dysfunction - orthostatic hypotension, constipation, urinary urgency/nocturia (38-71% of patients have lower urinary tract symptoms), sexual dysfunction, sialorrhea (drooling)
• Cognitive impairment/Dementia - emerges in many patients; if within 1 year of motor onset, termed Lewy Body Dementia (LBD)
• Olfactory loss (hyposmia) - often an early pre-motor symptom
• Pain and fatigue
• Guyton & Hall; Bradley & Daroff's Neurology; Robbins

Disease Progression

7. Diagnosis

• Bradykinesia PLUS at least one of: rest tremor, muscular rigidity
• Response to levodopa supports diagnosis

• CT/MRI brain: to rule out vascular parkinsonism, normal pressure hydrocephalus (NPH), structural lesions
• DaT scan (dopamine transporter SPECT): shows reduced uptake in the striatum; useful in differentiating PD from essential tremor
• PET with FDG: reduced uptake in striatum
• Neurologist referral when parkinsonism-plus syndrome is suspected
• Textbook of Family Medicine 9e

Differential Diagnosis (Parkinsonism-Plus Syndromes)

• Robbins & Kumar; Adams & Victor's

8. Treatment

When to Start

Pharmacotherapy

A. Levodopa + Carbidopa (Gold Standard)

• Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in surviving nigral neurons
• Given alone, it is rapidly metabolized peripherally to dopamine (which cannot cross the BBB), causing nausea, vomiting, and hypotension
• Carbidopa is a peripheral dopa-decarboxylase inhibitor; combined with levodopa, it prevents peripheral conversion, reducing dose needed and side effects
• Standard starting dose: carbidopa/levodopa 25 mg/100 mg three times daily
• Most effective for bradykinesia and rigidity; limited effect on non-motor symptoms
• Long-term complications: motor fluctuations ("wearing off" between doses), "on-off" phenomena, dyskinesias (involuntary movements)

B. Dopamine Agonists

• Pramipexole, ropinirole, rotigotine (patch), apomorphine
• Act directly on striatal dopamine receptors; useful as initial therapy or adjunct to levodopa
• Longer duration of action than levodopa; fewer motor fluctuations initially
• Side effects: excessive daytime sleepiness, impulse control disorders, hallucinations (especially in elderly)

C. MAO-B Inhibitors

• Selegiline, rasagiline
• Inhibit monoamine oxidase type B, which metabolizes dopamine - prolonging its action
• May also slow neurodegeneration (neuroprotective effect debated)
• Used as monotherapy in early disease or adjunct in later disease
• Effective combination with L-dopa for better control

D. COMT Inhibitors

• Entacapone, tolcapone
• Inhibit catechol-O-methyltransferase, another enzyme metabolizing dopamine
• Used as adjuncts to carbidopa/levodopa to prevent motor fluctuations ("wearing off")
• Tolcapone requires liver function monitoring (hepatotoxicity risk)
• Stalevo = carbidopa + levodopa + entacapone in one tablet

E. Anticholinergics

• Trihexyphenidyl (Artane), benztropine (Cogentin)
• Useful primarily for tremor
• Avoid in elderly (impaired memory, urinary retention, blurred vision)

F. Amantadine

• Modest anti-parkinsonian effects; also useful for levodopa-induced dyskinesias
• NMDA glutamate receptor antagonist

Drug Summary Table

• Textbook of Family Medicine 9e; Guyton & Hall; Neuroanatomy through Clinical Cases

Non-Pharmacological Treatment

• Physical therapy: gait training, balance exercises, strength training. A 2025 network meta-analysis (PMID 39880702) found that exercise meaningfully improves motor symptoms; optimal dose and type vary by outcome
• Virtual reality therapy: 2025 meta-analysis (PMID 40142335) found VR combined with conventional therapy improves balance beyond conventional therapy alone
• Speech therapy: for hypophonia and dysphagia (LSVT-LOUD program)
• Occupational therapy: adaptive strategies, fall prevention
• Nutritional support: addressing dysphagia, constipation
• Management of neuropsychiatric symptoms: cognitive behavioral therapy, pharmacologic management of anxiety (PMID 40568748)

Surgical Treatment: Deep Brain Stimulation (DBS)

• Subthalamic nucleus (STN): slightly larger benefit in medication-off state; may allow larger dopamine medication reductions; higher risk of neuropsychiatric side effects
• Globus pallidus internus (GPi): better dyskinesia suppression, better long-term flexibility, relatively safer neuropsychiatric profile; preferred for "brittle" dyskinesia (occurring at very low medication doses)

Experimental/Emerging Therapies

• Cell transplantation: fetal dopamine-secreting cells transplanted into caudate/putamen (some short-term success); stem cell strategies under investigation
• Alpha-synuclein targeting: immunotherapy approaches attempting to remove α-synuclein aggregates (mostly unsuccessful so far)
• Gene therapy: targeting specific pathways - Adams & Victor's; Guyton & Hall

9. Complications

• Motor fluctuations: "wearing off," "on-off" phenomena
• Levodopa-induced dyskinesias: chorea, dystonia
• Aspiration pneumonia: from dysphagia - leading cause of death
• Falls and fractures: from postural instability
• Dementia: affects a large proportion in later stages
• Depression/anxiety: highly prevalent, affects quality of life
• Autonomic failure: orthostatic hypotension, urinary dysfunction, constipation
• Psychosis/Hallucinations: particularly with dopaminergic medications (and in Lewy Body Dementia)

10. Key Summary Points